BUZZ-Australia's Saluda Medical rises as FDA approves pain-treatment device for US market

Sutherland Asset Management Corp

Sutherland Asset Management Corp

SLD

0.00

** Shares of Australia's Saluda Medical SLD.AX rise as much as 24.4% to A$0.510, hitting their highest level since May 15

** Stock on track for its best day since June 2, if gains hold

** The medical device firm says the U.S. Food and Drug Administration (FDA) has approved its CAP24 paddle lead

** Adds that approval allows the product to be marketed and sold in the U.S.

** Paddle lead is a medical device used in Spinal Cord Stimulation to treat chronic back, arm, or leg pain

** Stock down over 65% this year, including the day's move


This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.